Altimmune announces initiation of phase 2b impact trial evaluating the efficacy and safety of pemvidutide in non-alcoholic steatohepatitis (nash)

Gaithersburg, md., aug. 01, 2023 (globe newswire) -- altimmune, inc. (nasdaq: alt), a clinical-stage biopharmaceutical company, today announced that it has enrolled the first subject in the phase 2b impact trial evaluating the efficacy and safety of pemvidutide in subjects with non-alcoholic steatohepatitis (nash). pemvidutide is a novel, investigational glp-1/glucagon dual receptor agonist under development for the treatment of obesity and nash.
ALT Ratings Summary
ALT Quant Ranking